Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Shein Shares Slide 9% in Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
OpenAI Rejects Apple Trade Secret Theft Claims 
France Targets Shein, Temu With Fast-Fashion Fees 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Add as a preferred source on Google
NEW YORK, March 19, 2018 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Schmidt, Ph.D. will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. Dr. Schmidt will focus on the coverage of Biotech companies, working closely with our growing therapeutics team.
Dr. Schmidt will join Guggenheim from LEERINK Partners, where he has been an equity research analyst since 2009 and was named runner-up in the 2017 Institutional Investor All-America Research Survey in the Biotech/Mid- & Small-Cap category. Previous to joining LEERINK in 2009, he was a healthcare analyst and consultant for Susquehanna International Group’s private equity team. Dr. Schmidt was a research fellow at Harvard University previous to his work at Susquehanna.
“We are excited to have Michael join our growing healthcare equity research team,” said Stefano Natella, Director of Equity Research. “He represents an important next step in our plan to invest substantially in our research capabilities, particularly in the healthcare sector. We look forward to his continued success at Guggenheim.”
Michael Schmidt received his Ph.D. and M.Sc. from the University of Stuttgart in biochemistry and molecular genetics, respectively.
About Guggenheim Securities
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at [email protected] or 212.518.9200.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $305 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.
Media Contact
Ellen Cunningham
Guggenheim Partners
212.518.9578
[email protected]
